Buy Senores Pharma; target of Rs 1700: Choice Institutional Equities

Moneycontrol • 2 days ago

Original source

Key Investment Pillars

  • Regulated Markets Growth: The company's regulated markets business is expected to drive growth, supported by a robust pipeline of 41 approved ANDAs, including 4-5 controlled substance launches, and the commercialization of Zoraya and Amerisyn.
  • Emerging Markets Expansion: Emerging markets are expected to contribute to growth, with over 500 approved products and 944 registrations under review, providing a healthy launch pipeline.
  • Branded Generics Profitability: The India branded generics business is focused on profitability, with a successful shift towards premium products and better pricing discipline.
  • Operational Efficiency: The company is expected to maintain its operational efficiency, with a focus on cost discipline and margin expansion.

Thesis Validation Checklist

To validate the investment thesis, investors should monitor the following signals over the next 12 months:

  • Revenue growth: The company's ability to deliver revenue growth in line with its guidance of 30-40% for FY27.
  • EBITDA margin expansion: The company's ability to expand its EBITDA margin, with a forecast of 28-30% for FY27-29E.
  • Product launches: The successful launch of new products, including controlled substance products, and the commercialization of Zoraya and Amerisyn.
  • Emerging markets growth: The growth of emerging markets, with a focus on the rollout of GLP-1 products across 18-20 markets. If these signals are positive, it would indicate that the company is on track to deliver strong earnings growth and justify its 'BUY' rating.